From High Hopes to Hard Times: The Fall of a Gene Therapy Pioneer
Bluebird Bio, once a shining star in the biotech world, is now a shadow of its former self. The company, known for its groundbreaking gene therapies, has been sold to private equity firms Carlyle and SK Capital for a mere $30 million. This sale marks the end of a long and tumultuous journey for Blue